136 related articles for article (PubMed ID: 36975091)
1. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma.
Miura Y; Motoshima T; Anami T; Yano H; Mito R; Pan C; Urakami S; Kinowaki K; Tsukamoto H; Kurahashi R; Murakami Y; Yatsuda J; Fujiwara Y; Kamba T; Komohara Y
Microbiol Immunol; 2023 Jul; 67(7):345-354. PubMed ID: 36975091
[TBL] [Abstract][Full Text] [Related]
2. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
3. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
4. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A; Gonnin C; Phan L; Saldmann A; Granier C; Lillo-Lelouet A; Le Beller C; Pouchot J; Weiss L; Tartour E; Fabre E; Medioni J; Oudard S; Vano YA; Dragon-Durey MA; Simonaggio A
Oncoimmunology; 2023; 12(1):2204754. PubMed ID: 37187974
[TBL] [Abstract][Full Text] [Related]
5. MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Nagasaka H; Kishida T; Kouro T; Igarashi Y; Takebe S; Yamamoto S; Kondo T; Koizumi M; Terao H; Suzuki T; Nakaigawa N; Himuro H; Wei F; Sasada T
Int J Clin Oncol; 2024 Jun; 29(6):832-839. PubMed ID: 38580797
[TBL] [Abstract][Full Text] [Related]
6. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
7. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Seethapathy H; Street S; Strohbehn I; Lee M; Zhao SH; Rusibamayila N; Chute DF; Gao X; Michaelson MD; Rahma OE; Choueiri TK; McGregor B; Sonpavde G; Salabao C; Kaymakcalan MD; Wei X; Gupta S; Motwani S; Leaf DE; Reynolds KL; Sise ME
Eur J Cancer; 2021 Nov; 157():50-58. PubMed ID: 34482189
[TBL] [Abstract][Full Text] [Related]
10. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.
Alserawan L; Anguera G; Zamora Atenza C; Serra López J; Martínez-Martínez L; Riudavets Melià M; Sullivan I; Barba Joaquin A; Majem Tarruella M; Vidal S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293498
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract][Full Text] [Related]
13. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
14. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
Front Immunol; 2022; 13():931429. PubMed ID: 36248782
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
16. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
[TBL] [Abstract][Full Text] [Related]
17. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
[TBL] [Abstract][Full Text] [Related]
18. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract][Full Text] [Related]
20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
